North East and North Cumbria
ICS Formulary
Home
About
Admin
netFormulary
Chapters
Medicines A-Z
News
Mobile
Reports
Feedback
Search
Recent Updates - Updated items
All Formulary Amendments
Records 1 to 11 of 11
Details
LDL
Link Added : MHRA Drug Safety Update (May 2016): BCR-ABL tyrosine kinase inhibitors: risk of hepatitis B reactivation : https://www.gov.uk/drug-safety-update/bcr-abl-tyrosine-kinase-inhibitors-risk-of-hepatitis-b-reactivation
11/07/2023 17:50:05
(dmcdermott )
UPD
sitematrix Changed from 0 to
11/07/2023 17:49:35
(dmcdermott )
UPD
FurtherInformation Changed from
Approved as an option for the treatment of chronic, accelerated blast phase Philidephia chromosome positive chronic myeloid leukaemia in adults when they have previously had 1 or more tyrosine kinase
11/07/2023 17:49:35
(dmcdermott )
UPD
Bosutinib (Bosulif
®
) =
11/07/2023 17:49:35
(dmcdermott )
UPD
Bosutinib (Bosulif
®
) changed to protein kinase inhibitor
09/05/2018 11:17:05
(LoweryM )
UPD
Bosutinib (Bosulif
®
) updated
09/05/2018 11:10:11
(LoweryM )
UPD
Bosutinib (Bosulif
®
) updated
09/05/2018 11:10:03
(LoweryM )
UPD
Bosutinib updated
09/05/2018 11:08:40
(LoweryM )
UPD
Bosutinib approved
11/08/2017 15:24:09
(LoweryM )
UPD
Bosutinib b
01/02/2017 14:35:22
(DavidS )
UPD
Bosutinib b
23/01/2017 15:27:22
(WhitehallJ )
